Fra-1 downregulation contributes to the anti-invasive effect of ectopic miR-34a re-expression in colorectal and breast cancer [15,16], thus suggesting the efficacy of miR-34a-based drugs against Fra-1-overexpressing tumors. This evidence concerns the gene FOSL1 and breast carcinoma.